Navigation Links
Hospira Announces CEO Succession Plan
Date:8/20/2010

LAKE FOREST, Ill., Aug. 20 /PRNewswire-FirstCall/ -- The board of directors of Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced that Christopher B. Begley, chairman and chief executive officer (CEO), has indicated his intent to retire from the CEO position after more than six years of dedicated service. Begley will serve as CEO until his successor is named. He will then remain an employee of the company as executive chairman of the Hospira board, ensuring continuity of leadership and an orderly transition of his CEO responsibilities.

"Launching Hospira as an independent company has been the most rewarding experience of my three decades in healthcare, and I've been extremely privileged to work with such a talented and dedicated team of employees to advance wellness for our stakeholders around the globe," said Begley. "Over the last six years we have transformed this company from one of declining sales and margins to strong growth and profitability, and the time is right for a new CEO to lead Hospira on its patient-focused journey to sustainable top-tier financial performance. I look forward to remaining an active contributor to Hospira, confident the company is stronger and better positioned for success now than at any point in our rich history."

As the company's founding CEO, Begley oversaw Hospira's 2004 spin-off from Abbott Laboratories, drove the development of the company's business strategies and growth plans, and created the company's guiding principles -- its vision, values and stakeholder commitments. During his tenure, Begley doubled Hospira's geographic footprint and revenue outside the United States, improved adjusted gross margins by more than 1,000 basis points, generated more than $3 billion in cash flow from operations, and doubled its market capitalization.

In 2009, Begley launched Proj
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. Hospira Reports Third-Quarter 2009 Results
7. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
8. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
9. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... , July 30, 2015 Takeda Pharmaceutical ... study to fulfill the post-marketing commitment and submissions ... Pan European Multi-Database Bladder Cancer Risk Characterization Study ... cohort study, conducted in four European countries, for ... up to 10 years of follow-up. Findings demonstrate ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... ... Reportlinker.com announces that a new market research report ... Markets for Breast Biopsy Devices 2009 , ... markets for breast biopsy devices includes the spring ...
... , NATICK, Mass. and LONDON, Nov. ... ) today announced that it has received 510(k) clearance ... CE Mark approval to market its WallFlex® Fully Covered ... (obstructions) caused by tumors in patients with resectable or ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This is ... Dr. Clevens has worked closely with the university, developing a strong presence and a ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston Web Marketing ... Summit. Google Partners is the platform for search marketing agencies to communicate with ... tools necessary to run successful search marketing campaigns. Google Partners also affords businesses ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy ... nonsurgical treatment designed specifically for the elimination of excess tissue under the ... locations in the state of Wisconsin to offer this innovative treatment. , Developed by ...
(Date:7/30/2015)... ... 30, 2015 , ... The American Association of Poison Control ... the reinstitution of National Prescription Drug Take-Back Days. The 10th event of this ... 2:00 PM local time. On the 26th, the DEA, with the assistance of ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3
... ... them , ... 2010 -- Still hunting for the perfect Mother,s Day gift idea? While it,s wonderful to ... universally don,t have enough of is sleep. With Mother,s Day right around the corner on May ...
... ... Assess & Treat the Country’s Pest Management Needs, , ... (PRWEB) April 29, 2010 -- Most people are aware of the ... January 12th. While the country is still dealing with widespread damage to its infrastructure ...
... Geneva, 29 April 2010 -- Lung cancer patients whose tumors ... than those who do not, Canadian researchers have found. Their ... Geneva, highlights the exciting possibility that the molecule could soon ... is a receptor that is found on the surface of ...
... Practicing non-pharmaceutical interventions (NPIs) such as hand-washing and ... pandemic flu, but more research on these measures is ... May issue of AJIC : American Journal ... Association for Professionals in Infection Control and Epidemiology, Inc. ...
... ... errors and boost quality of service , ... Trevose, PA (PRWEB) April 29, 2010 -- Airclic, ... logistics and field service operations, today introduced Clinical Perform, a SaaS-based mobile software product ...
... clumps of protein, not plaques, may cause the disease, ... research could change the way scientists view the causes -- ... A study published online this month in the Annals ... (abeta) proteins called oligomers could be a prime cause of ...
Cached Medicine News:Health News:The Perfect Mother's Day Gift Idea: A Good Night's Sleep 2Health News:Clark Pest Control Executive Asked to Aid Haitian Government with Post-Earthquake Pest Issue 2Health News:Clark Pest Control Executive Asked to Aid Haitian Government with Post-Earthquake Pest Issue 3Health News:CXCR4: A new drug target in lung cancer 2Health News:Hand-washing, mask-wearing may limit transmission of pandemic flu 2Health News:Hand-washing, mask-wearing may limit transmission of pandemic flu 3Health News:Airclic Introduces Clinical Perform™ 2Health News:Airclic Introduces Clinical Perform™ 3Health News:New Finding Could Mark Shift in Alzheimer's Research 2Health News:New Finding Could Mark Shift in Alzheimer's Research 3
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... an X-ray contrast medium for ... for: angiography, urography, phlebography and ... of the basal cisterns, following ... cholangio (pancreato) graphy (ERC(P)), herniography, ...
... (gadobenate dimeglumine) is a paramagnetic MRI contrast ... with gadobenate, a chelating agent that forms ... godolinium ion. It is salified with meglumine ... with all the physico-chemical features typical of ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
Medicine Products: